Pacific Biosciences
PACB
PACB
270 hedge funds and large institutions have $3.37B invested in Pacific Biosciences in 2023 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 99 increasing their positions, 63 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
15% more capital invested
Capital invested by funds: $2.93B → $3.37B (+$444M)
5% more funds holding
Funds holding: 257 → 270 (+13)
1% less ownership
Funds ownership: 102.54% → 101.54% (-1%)
Holders
270
Holding in Top 10
6
Calls
$47.5M
Puts
$25.4M
Top Buyers
| 1 | +$26.4M | |
| 2 | +$17.3M | |
| 3 | +$13.2M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.3M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$11.2M |
Top Sellers
| 1 | -$47.6M | |
| 2 | -$27.3M | |
| 3 | -$18.5M | |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$15.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$15M |